8-K: Cognition Therapeutics Stockholders Elect Directors and Ratify Auditor at Annual Meeting

Cognition Therapeutics, Inc. announced the successful election of two Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Summary

• Cognition Therapeutics, Inc. held its Annual Meeting of Stockholders virtually on June 18, 2025.
• Stockholders elected Peggy Wallace as a Class I director with 8,566,458 votes For and 2,590,981 votes Withheld, along with 22,760,336 broker non-votes.
• Ellen B. Richstone was also elected as a Class I director, receiving 8,686,877 votes For and 2,470,562 votes Withheld, with 22,760,336 broker non-votes.
• Both elected Class I directors will serve until the company's 2028 Annual Meeting of Stockholders.
• The appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the 2025 fiscal year was ratified by stockholders.
• The auditor ratification received 33,457,921 votes For, 327,242 votes Against, and 132,612 Abstentions, with no broker non-votes.

Sentiment

Score: 7

Explanation: The document reports the successful completion of routine corporate governance matters (director elections and auditor ratification) with no contentious outcomes or negative surprises, indicating a stable and expected operational update.

Positives

• The company successfully elected its proposed Class I directors, Peggy Wallace and Ellen B. Richstone, ensuring continuity in board leadership.
• The appointment of Ernst & Young LLP as the independent auditor for 2025 was overwhelmingly ratified by stockholders, indicating strong confidence in the company's financial oversight.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding future performance or strategic initiatives.

Industry Context

This 8-K filing is a standard disclosure of annual meeting voting results, which is common across all publicly traded companies. It does not provide specific industry context or trends relevant to the biotechnology or pharmaceutical sector in which Cognition Therapeutics operates.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry benchmarks, comparable companies, or projects. The voting results for director elections and auditor ratification are typical corporate governance procedures.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The successful election of directors and ratification of auditors provides clarity on corporate governance and financial oversight, which can contribute to investor confidence.
• Management/Board: The election of directors ensures continuity in leadership and strategic direction.

Next Steps

• The newly elected Class I directors, Peggy Wallace and Ellen B. Richstone, will serve until the company's 2028 Annual Meeting of Stockholders.
• Ernst & Young LLP will serve as the company's independent registered public accounting firm for the 2025 fiscal year.

Key Dates

Keywords

Cognition Therapeutics, CGTX, Annual Meeting, Stockholders Meeting, Director Election, Auditor Ratification, Corporate Governance, SEC Filing, 8-K, Peggy Wallace, Ellen B. Richstone, Ernst & Young LLP